For the FDA-approved targeted therapies, there is a wide range of response rates, from approximately 30% with trastuzumab in breast cancer with HER2/Neu overexpression and/or gene amplification [32], 60% with vemurafenib in melanoma with a BRAF mutation [33,34], to over 90% in chronic myeloid leukemia [35,36]. This evidence concerns the gene ERBB2 and chronic myelogenous leukemia, BCR-ABL1 positive.